Evidence map›Paper›PMID 39832211›Full record

ArticleCancer science2025

A Phase I, First-In-Human Study of CBA-1205, an Anti-DLK1 Monoclonal Antibody, in Patients With Advanced Solid Tumors.

Yuki Katsuya, Masafumi Ikeda, Takafumi Koyama, Jun Sato, Mao Okada, Nobuaki Matsubara, Chihiro Kondoh, Toru Mukohara, Kazuo Watanabe, Daisuke Kotani and 3 more

Registry-linked trialAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06636435 (A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors.), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06636435 phase1recruitingnot on this map

A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors.

TypeinterventionalSponsorChiome Bioscience Inc.Ran2020 to 2027Enrolled66ConditionsSolid Tumors, Hepatocellular Carcinoma (HCC), Malignant Melanoma, Pediatric CancerArmsCBA-1205 Part 1, CBA-1205 Part 2, CBA-1205 Part 3, CBA-1205 Part 4, CBA-1205 Part 5
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. DLK1: a novel therapeutic target in cancer.Endocrine-related cancer · 2026
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yuki KatsuyaDepartment of Experimental Therapeutics, National Cancer Center Hospital, Chuo-ku, Japan.ORCID https://orcid.org/0000-0002-2127-3601
Masafumi IkedaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.ORCID https://orcid.org/0000-0002-4050-2086
Takafumi KoyamaDepartment of Experimental Therapeutics, National Cancer Center Hospital, Chuo-ku, Japan.ORCID https://orcid.org/0000-0001-5807-8458
Jun SatoDepartment of Experimental Therapeutics, National Cancer Center Hospital, Chuo-ku, Japan.ORCID https://orcid.org/0000-0001-9249-6522
Mao OkadaDepartment of Experimental Therapeutics, National Cancer Center Hospital, Chuo-ku, Japan.
Nobuaki MatsubaraDepartment of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.ORCID https://orcid.org/0000-0002-9203-4245
Chihiro KondohDepartment of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Toru MukoharaDepartment of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.ORCID https://orcid.org/0000-0002-8573-418X
Kazuo WatanabeDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.ORCID https://orcid.org/0000-0002-1810-5308
Daisuke KotaniDepartment of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Yoshimi OgawaChiome Bioscience Inc, Tokyo, Japan.ORCID https://orcid.org/0009-0007-2220-9576
Shose TaokaChiome Bioscience Inc, Tokyo, Japan.
Noboru YamamotoDepartment of Experimental Therapeutics, National Cancer Center Hospital, Chuo-ku, Japan.ORCID https://orcid.org/0000-0002-0787-2851

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CBA-1205 is a novel humanized antibody targeting delta-like 1 homolog (DLK1) that enhances antibody-dependent cellular cytotoxicity activity. DLK1 overexpression has been reported in various cancer types, such as hepatocellular carcinoma and neuroblastoma. CBA-1205 demonstrates potent antitumor activity in multiple tumor models, making it a potential treatment option for DLK1-expressing cancers. This first-in-human, open-label Phase I study includes three parts. Part 1, the dose-escalation phase, primarily evaluates the safety profile, tolerability, and maximum tolerated dose of CBA-1205. The drug is administered intravenously every 2 weeks in a 28-day cycle. A standard 3 + 3 dose-escalation design was used across seven cohorts. In a cohort of 22 Japanese patients, over 80% had undergone three or more prior treatments. CBA-1205 was well tolerated, with no dose-limiting toxicity observed at doses ranging from 0.1 to 30 mg/kg, the planned highest dose. There were no treatment-related serious adverse events or trial-related deaths. CBA-1205 exposure, as measured by C

Indexed as

Antibodies, Monoclonal, HumanizedMembrane ProteinsNeoplasmsAdultAgedAged, 80 and overCalcium-Binding ProteinsFemaleHumansMaleMaximum Tolerated DoseMiddle AgedAntibodies, Monoclonal, HumanizedCalcium-Binding ProteinsDLK1 protein, humanMembrane ProteinsantibodyCBA‐1205DLK1first in humanphase I

Identifiers

PMID39832211
PMCPMC11967245

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.